Lantheus Holdings, Inc. announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD has been named Chief Science Officer (CSO), effective May 28, 2024. Dr. Humphrey is a seasoned leader in drug development and a physician-scientist with more than 30 years of experience in clinical oncology, neuroscience, cancer research, and drug discovery, having led organizations developing drugs from pre-IND through launch. As CMO, he will oversee Lantheus?

research and development organization, including research and pharmaceutical development, regulatory affairs, clinical development, medical affairs, and isotope strategy. Dr. Humphrey spent more than two decades working for global pharmaceutical companies, including Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer, and subsequently held senior leadership positions at multiple clinical-stage biotechnology companies. Dr. Humphrey earned a Doctorate in Medicine from Case Western Reserve University School of Medicine and an AB in Applied Mathematics from Harvard University.

He is Board Certified in Oncology and Internal Medicine and has published more than 30 peer-reviewed papers in molecular biology and clinical research. Dr. Jean-Claude Provost, in his new CSO role, will support Lantheus? business development activities to advance and enhance the Company?s pipeline and capabilities.

Dr. Provost offers a wealth of scientific acumen, extensive research and development experience, and deep radiopharmaceutical and industry knowledge. Dr. Provost has more than thirty years of experience in the international development of therapeutic drugs and diagnostic agents for global companies, including GE Healthcare?s pharmaceutical diagnostics division, Pfizer, Merck-Serono and Bayer. Dr. Provost holds degrees in Methodology and Statistics and Clinical Pharmacology from the University of Paris and a Doctorate in Medicine from Sorbonne University, Paris.